Vytrus Biotech (XMAD:VYT) Beta: -0.1119 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:VYT Vytrus Biotech SA XMAD:VYT
66 GF Score
Price €15.60
GF Value €5.67
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Beta?

Vytrus Biotech XMAD:VYT +4.00% 66 Beta is -0.1119 as of Aug. 24, 2026. GuruFocus rates XMAD:VYT with a GF Score™ of 66/100 and a GF Value™ of €5.67 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-24), Vytrus Biotech's Beta is -0.1119.


Vytrus Biotech  (XMAD:VYT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Vytrus Biotech Beta Related Terms


Vytrus Biotech Beta Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Beta Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.35

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.21 0.35

XMAD:VYT vs VRTX, REGN, RVMD: Beta Comparison

For the Biotechnology subindustry, Vytrus Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vytrus Biotech Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Vytrus Biotech's Beta falls into.


XMAD:VYT
66GF Score
Vytrus Biotech SA XMAD:VYT
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.1119 mean?
Vytrus Biotech (XMAD:VYT) has a Beta of -0.1119 as of Aug. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Vytrus Biotech and its competitors.
Is Vytrus Biotech's Beta too high?
Vytrus Biotech's current Beta is -0.1119. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Beta compare to VRTX and REGN?
Vytrus Biotech's Beta of -0.1119 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Vytrus Biotech and its competitors. Vytrus Biotech's current Beta is -0.1119. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.67, compared to a current price of €15.60 — trading 175.1% above its estimated fair value. The current Beta is -0.1119. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Beta is -0.1119 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €15.60 is trading 175.1% above its estimated GF Value™ of €5.67. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for XMAD:VYT:

  • Beta: -0.1119
  • GF Value™: €5.67 vs. price of €15.60 (175.1% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vytrus Biotech Business Description

Other Exchanges V5P:Germany
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score

Get the complete analysis for XMAD:VYT

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.60
Price
€5.67
GF Value